An adolescent patient, aged 15, is accompanied by her mother to the outpatient clinic for evaluation of delayed puberty. She reports that she has never experienced a menstrual period. On physical examination, her height is at the 3rd percentile for her age. She has Tanner stage 1 breast development and Tanner stage 1 pubic hair. Her vital signs are within normal limits. Assuming the patient's evaluation follows the most likely etiologic pathway for her clinical presentation, arrange the following diagnostic and management steps in the most appropriate chronological order.
- 1Perform a transabdominal pelvic ultrasound
- 2Measure the serum follicle-stimulating hormone (FSH) level
- 3Obtain a karyotype analysis from peripheral blood
- 4Perform transthoracic echocardiography and renal ultrasonography
- 5Initiate low-dose transdermal estradiol therapy
Cevap
The correct chronological order is: 1) Pelvic ultrasound, 2) Serum FSH level, 3) Karyotype analysis, 4) Echocardiography and renal ultrasonography, 5) Estrogen therapy.
The correct sequence follows the standard algorithmic approach for primary amenorrhea. The presence of a uterus must first be confirmed (pelvic ultrasound). Given the absence of secondary sexual characteristics, an FSH level is then drawn to differentiate central from peripheral causes. The patient's short stature makes Turner syndrome highly likely, which classically presents with elevated FSH (hypergonadotropic hypogonadism), necessitating a karyotype for definitive diagnosis. Once Turner syndrome (45,X) is confirmed, screening for associated life-threatening anomalies (e.g., coarctation of the aorta) via echocardiography must occur. Finally, hormone replacement therapy is initiated to induce puberty.
Adım Adım Çözüm
Anahtar Kavram
The evaluation of primary amenorrhea begins with a pelvic ultrasound to verify the presence of a uterus, followed by FSH measurement if breast development is absent, and karyotyping if FSH is elevated; a diagnosis of Turner syndrome then requires screening for structural anomalies before initiating estrogen therapy.